Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review

Linden, M.M.D. van der; Rappard, Dominique C. van; Daams, Joost G.; Sprangers, Mirjam A. G.; Spuls, Phyllis I.; Korte, J. de

doi:10.2340/00015555-1976

Cited by 55 publications

(33 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the onset of the disease, patients with rosacea will experience cycles of relapse and remission of symptoms throughout their lives. Rosacea is known to have a negative impact on quality of life and is associated with depression and social isolation, hampering both social and professional lives . In a recent National Rosacea Society survey of 1675 patients, 68% of patients with mild rosacea reported an adverse impact on their general outlook on life, with this negative impact increasing to 87% and 95% in patients with moderate and severe symptoms, respectively, highlighting that the emotional impact on patients appears to increase as symptoms become more severe…”

Section: Introductionmentioning

confidence: 99%

Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36‐week extension of the ATTRACT randomized study

Taı̈eb

Khemis

Ruzicka

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36‐week extension of the ATTRACT randomized study

Taı̈eb

Khemis

Ruzicka

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The patient burden of rosacea can be significant . However, few tools exist to measure the psychosocial burden of rosacea and, like severity scales, many are repurposed from other areas, with a variety used across the literature . RosaQoL is the only quality‐of‐life instrument specific to rosacea.…”

Section: Existing Scales For Different Clinical Features Of Rosaceamentioning

confidence: 99%

Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROS acea CO nsensus ( ROSCO ) panel

et al. 2017

View full text Add to dashboard Cite

SummaryBackground Rosacea is currently diagnosed by consensus-defined primary and secondary features and managed by subtype. However, individual features (phenotypes) can span multiple subtypes, which has implications for clinical practice and research. Adopting a phenotype-led approach may facilitate patient-centred management. Objectives To advance clinical practice by obtaining international consensus to establish a phenotype-led rosacea diagnosis and classification scheme with global representation. Methods Seventeen dermatologists and three ophthalmologists used a modified Delphi approach to reach consensus on statements pertaining to critical aspects of rosacea diagnosis, classification and severity evaluation. All voting was electronic and blinded. Results Consensus was achieved for transitioning to a phenotype-based approach to rosacea diagnosis and classification. The following two features were independently considered diagnostic for rosacea: (i) persistent, centrofacial erythema associated with periodic intensification; and (ii) phymatous changes. Flushing, telangiectasia, inflammatory lesions and ocular manifestations were not considered to be individually diagnostic. The panel reached agreement on dimensions for phenotype severity measures and established the importance of assessing the patient burden of rosacea. Conclusions The panel recommended an approach for diagnosis and classification of rosacea based on disease phenotype.

show abstract

“…As rosacea affects facial appearance, the condition can have a marked psychological impact and undermine health-related quality of life 3,7–9. As Moustafa et al commented, “… patients with dermatologic conditions bear their disease for the world to see” 7.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin

Grivet-Seyve

Santoro

Lachmann

2017

CCID

View full text Add to dashboard Cite

Background/objectiveRosacea-prone sensitive skin requires high sun-protection factor (SPF) moisturizers. This study evaluated Daylong Extreme SPF 50+ lotion, a novel cream containing five ultraviolet filters, two emollients, and three skin conditioners.Subjects and methodsThis was an open-label, single-center study. On day 1, before treatment, subjects answered a questionnaire on their skin conditions and sunscreen habits, and both subjects and dermatologist evaluated skin status. Subjects applied the product once daily in the morning to the face for 21 days, and after approximately 3–5 minutes they assessed tolerability and short-term cosmetic acceptability in a questionnaire and daily diary. On day 22, the dermatologist and subjects evaluated skin status for long-term tolerance and cosmetic acceptability.ResultsThe study enrolled 44 individuals (mean age 58.8 years, 91% female). At baseline, most subjects (39 of 44) showed erythema, and ~30% showed dryness and scaling. Dermatologists noted four cases of pustules and one case of papules. After 21 days’ treatment with the product, the dermatologist reported significantly less erythema, dryness and scaling, three cases of pustules and two cases of papules. At baseline, ~75% of subjects noted a feeling of dryness, >50% reported tension, and nearly 25% reported tickling. After using the product for 21 days, subjects reported significantly less tension, dryness, and tickling. Some subjects noted itching and burning before and after using the product. One subject noted papules during treatment. Most subjects said that the product was pleasant, did not irritate the skin or cause stinging/burning, was easy to apply, quickly absorbed, and nongreasy, improved skin moisturization, helped prevent sun-provoked facial redness, did not worsen rosacea, and was easily incorporated into their skincare regimen. Half would switch to the product, and 80% of subjects would buy and recommend the product.ConclusionThe product was well tolerated in rosacea-prone subjects, producing objective and subjective improvements in skin status and symptoms.

show abstract

Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review

Cited by 55 publications

References 41 publications

Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36‐week extension of the ATTRACT randomized study

Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36‐week extension of the ATTRACT randomized study

Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROS acea CO nsensus ( ROSCO ) panel

Evaluation of a novel very high sun-protection-factor moisturizer in adults with rosacea-prone sensitive skin

Contact Info

Product

Resources

About